| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary molecular target of rel-(8R,8'R)-dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan is not fully characterized, but the compound is known for its inhibitory effects on TNF-α production in mice. TNF-α is a key pro-inflammatory cytokine involved in immune responses and inflammation. By inhibiting TNF-α production, the compound may exert anti-inflammatory effects. The compound may also interact with other inflammatory signaling pathways, although its specific molecular targets require further investigation. As a natural product lignan, the compound may have additional biological activities, including antioxidant and anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro studies of this lignan are limited, as the compound is a natural product primarily used as a research reagent. The compound's inhibitory effect on TNF-α production has been demonstrated in mouse models. In cellular assays, the compound may be tested for its effects on cytokine production in immune cells stimulated with LPS or other inflammatory stimuli. The compound's stability in biological samples and its behavior under various analytical conditions have been characterized. It is also used as a standard in analytical chemistry for the identification and quantification of lignans in natural products. The compound's role as a natural product with anti-inflammatory activity makes it a useful tool for studying inflammatory pathways and natural product pharmacology.
|
| ln Vivo |
In vivo studies of rel-(8R,8'R)-dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan have demonstrated its significant inhibitory effects on TNF-α production in mice. The compound is a chemical constituent of nutmeg and may contribute to the anti-inflammatory properties of nutmeg extracts. In vivo protocols typically involve administration of the compound to mice via oral gavage or intraperitoneal injection. Endpoints include measurement of serum TNF-α levels after LPS challenge, assessment of inflammatory markers, and histopathological examination of tissues. The compound's anti-inflammatory activity supports its potential as a lead compound for developing anti-inflammatory therapeutics. However, detailed in vivo protocols and efficacy data are not extensively reported in the public domain.
|
| Enzyme Assay |
For TNF-α inhibition assays, the compound's effect on TNF-α production is typically assessed in vivo or in cell-based assays.
|
| Cell Assay |
For in vitro assays, immune cells (e.g., macrophages, monocytes) are cultured in appropriate medium and stimulated with LPS (0.1-1 µg/ml) in the presence or absence of the compound (0.1-100 µM). After 4-24 hours, culture supernatants are collected, and TNF-α levels are measured by ELISA. The compound's effect on other cytokines (e.g., IL-1β, IL-6) may also be assessed. For cytotoxicity assays, cell viability is assessed by MTT or LDH release. For mechanistic studies, cells are lysed and analyzed for inflammatory signaling proteins (e.g., NF-κB, MAPKs) by Western blot.
|
| Animal Protocol |
For in vivo studies, adult mice (6-8 weeks old) are used. The compound is dissolved in vehicle (e.g., 0.5% methylcellulose or saline with 0.5% DMSO) and administered orally or intraperitoneally at doses determined from preliminary studies (e.g., 1-50 mg/kg). For LPS-induced inflammation models, mice are treated with the compound 1-2 hours before LPS injection (5-10 mg/kg, i.p.). Blood samples are collected 2-6 hours after LPS challenge, and serum TNF-α levels are measured by ELISA. For chronic inflammation models, the compound may be administered daily for 1-2 weeks, and inflammatory markers are assessed. Body weights are monitored. Tissues (liver, spleen, lung) may be collected for histopathological examination and analysis of inflammatory markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for rel-(8R,8'R)-dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan are not available, as the compound is a natural product used primarily as a research reagent. As a lignan with moderate lipophilicity, the compound is expected to have moderate oral bioavailability and tissue distribution. Its metabolism likely involves hepatic CYP450 enzymes, including demethylation and oxidation. However, no dedicated pharmacokinetic studies have been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for this lignan are limited, as the compound is a natural product used as a research reagent. In preclinical studies, the compound has been shown to be well-tolerated at pharmacologically active doses. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As with all research compounds, appropriate safety precautions should be taken when handling this compound, including the use of personal protective equipment and work in a well-ventilated area.
|
| Additional Infomation |
Galbacin has been reported in Chamaecyparis obtusa var. . Data are available for Taiwan Magnolia, Magnolia officinalis, and Phoebe zhennan.
rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan (CAS 178740-32-4) is a naturally occurring lignan found in the fruit of Myristica fragrans (nutmeg) and in Saururus chinensis. It has significant inhibitory effects on TNF-α production in mice. Its molecular weight is 340.4. The compound is a lignan with a tetrahydrofuran core structure and two methylenedioxyphenyl groups. It is used as a research tool for studying anti-inflammatory mechanisms and natural product pharmacology. The compound is strictly for research use only. |
| Molecular Formula |
C20H20O5
|
|---|---|
| Molecular Weight |
340.3698
|
| Exact Mass |
340.131
|
| CAS # |
178740-32-4
|
| PubChem CID |
234441
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
460.6±45.0 °C at 760 mmHg
|
| Flash Point |
190.1±28.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
4.77
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
443
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1C(C(OC1C2=CC3=C(C=C2)OCO3)C4=CC5=C(C=C4)OCO5)C
|
| InChi Key |
QFUXQRHAJWXPGP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20O5/c1-11-12(2)20(14-4-6-16-18(8-14)24-10-22-16)25-19(11)13-3-5-15-17(7-13)23-9-21-15/h3-8,11-12,19-20H,9-10H2,1-2H3
|
| Chemical Name |
5-[5-(1,3-benzodioxol-5-yl)-3,4-dimethyloxolan-2-yl]-1,3-benzodioxole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9380 mL | 14.6899 mL | 29.3798 mL | |
| 5 mM | 0.5876 mL | 2.9380 mL | 5.8760 mL | |
| 10 mM | 0.2938 mL | 1.4690 mL | 2.9380 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
